Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: August 19, 2022

Investigational Drug Information for Darapladib

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Darapladib?

Darapladib is an investigational drug.

There have been 19 clinical trials for Darapladib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1^st 2008.

The most common disease conditions in clinical trials are Atherosclerosis, Myocardial Ischemia, and Coronary Artery Disease. The leading clinical trial sponsors are GlaxoSmithKline, The TIMI Study Group, and National Heart, Lung, and Blood Institute (NHLBI).

Summary for Darapladib

US Patents	0
International Patents	0
US Patent Applications	388
WIPO Patent Applications	191
Japanese Patent Applications	10
Clinical Trial Progress	Phase 3 (2008-12-01)
Vendors	73

Recent Clinical Trials for Darapladib

Title	Sponsor	Phase
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)	GlaxoSmithKline	Phase 1
Darapladib China PK	GlaxoSmithKline	Phase 1
Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects	GlaxoSmithKline	Phase 1

See all Darapladib clinical trials

Clinical Trial Summary for Darapladib

Top disease conditions for Darapladib

Top clinical trial sponsors for Darapladib

See all Darapladib clinical trials

US Patents for Darapladib

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Merck

Colorcon

Johnson and Johnson

Boehringer Ingelheim

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.